These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 10557054)

  • 1. The Tel-PDGFRbeta fusion gene produces a chronic myeloproliferative syndrome in transgenic mice.
    Ritchie KA; Aprikyan AA; Bowen-Pope DF; Norby-Slycord CJ; Conyers S; Bartelmez S; Sitnicka EH; Hickstein DD
    Leukemia; 1999 Nov; 13(11):1790-803. PubMed ID: 10557054
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tel/PDGFRbeta induces stem cell differentiation via the Ras/ERK and STAT5 signaling pathways.
    Dobbin E; Graham C; Corrigan PM; Thomas KG; Freeburn RW; Wheadon H
    Exp Hematol; 2009 Jan; 37(1):111-121. PubMed ID: 19100521
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fatal myeloproliferation, induced in mice by TEL/PDGFbetaR expression, depends on PDGFbetaR tyrosines 579/581.
    Tomasson MH; Sternberg DW; Williams IR; Carroll M; Cain D; Aster JC; Ilaria RL; Van Etten RA; Gilliland DG
    J Clin Invest; 2000 Feb; 105(4):423-32. PubMed ID: 10683371
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evidence for a role of NF-kappaB in the survival of hematopoietic cells mediated by interleukin 3 and the oncogenic TEL/platelet-derived growth factor receptor beta fusion protein.
    Besançon F; Atfi A; Gespach C; Cayre YE; Bourgeade MF
    Proc Natl Acad Sci U S A; 1998 Jul; 95(14):8081-6. PubMed ID: 9653143
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Myeloproliferative disease induced by TEL-PDGFRB displays dynamic range sensitivity to Stat5 gene dosage.
    Cain JA; Xiang Z; O'Neal J; Kreisel F; Colson A; Luo H; Hennighausen L; Tomasson MH
    Blood; 2007 May; 109(9):3906-14. PubMed ID: 17218386
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rabaptin-5 is a novel fusion partner to platelet-derived growth factor beta receptor in chronic myelomonocytic leukemia.
    Magnusson MK; Meade KE; Brown KE; Arthur DC; Krueger LA; Barrett AJ; Dunbar CE
    Blood; 2001 Oct; 98(8):2518-25. PubMed ID: 11588050
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Translocation (12;22) (p13;q11) in myeloproliferative disorders results in fusion of the ETS-like TEL gene on 12p13 to the MN1 gene on 22q11.
    Buijs A; Sherr S; van Baal S; van Bezouw S; van der Plas D; Geurts van Kessel A; Riegman P; Lekanne Deprez R; Zwarthoff E; Hagemeijer A
    Oncogene; 1995 Apr; 10(8):1511-9. PubMed ID: 7731705
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lhx2 expression in hematopoietic progenitor/stem cells in vivo causes a chronic myeloproliferative disorder and altered globin expression.
    Richter K; Pinto do O P; Hägglund AC; Wahlin A; Carlsson L
    Haematologica; 2003 Dec; 88(12):1336-47. PubMed ID: 14687986
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sensitivity to imatinib but low frequency of the TEL/PDGFRbeta fusion protein in chronic myelomonocytic leukemia.
    Gunby RH; Cazzaniga G; Tassi E; Le Coutre P; Pogliani E; Specchia G; Biondi A; Gambacorti-Passerini C
    Haematologica; 2003 Apr; 88(4):408-15. PubMed ID: 12681968
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The TEL/platelet-derived growth factor beta receptor (PDGF beta R) fusion in chronic myelomonocytic leukemia is a transforming protein that self-associates and activates PDGF beta R kinase-dependent signaling pathways.
    Carroll M; Tomasson MH; Barker GF; Golub TR; Gilliland DG
    Proc Natl Acad Sci U S A; 1996 Dec; 93(25):14845-50. PubMed ID: 8962143
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fusion of PDGF receptor beta to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation.
    Golub TR; Barker GF; Lovett M; Gilliland DG
    Cell; 1994 Apr; 77(2):307-16. PubMed ID: 8168137
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transgenic mice expressing Tel-FLT3, a constitutively activated form of FLT3, develop myeloproliferative disease.
    Baldwin BR; Li L; Tse KF; Small S; Collector M; Whartenby KA; Sharkis SJ; Racke F; Huso D; Small D
    Leukemia; 2007 Apr; 21(4):764-71. PubMed ID: 17268528
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Signal transduction and transforming properties of the TEL-TRKC fusions associated with t(12;15)(p13;q25) in congenital fibrosarcoma and acute myelogenous leukemia.
    Liu Q; Schwaller J; Kutok J; Cain D; Aster JC; Williams IR; Gilliland DG
    EMBO J; 2000 Apr; 19(8):1827-38. PubMed ID: 10775267
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia.
    Pikman Y; Lee BH; Mercher T; McDowell E; Ebert BL; Gozo M; Cuker A; Wernig G; Moore S; Galinsky I; DeAngelo DJ; Clark JJ; Lee SJ; Golub TR; Wadleigh M; Gilliland DG; Levine RL
    PLoS Med; 2006 Jul; 3(7):e270. PubMed ID: 16834459
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The TEL/ETV6 gene is required specifically for hematopoiesis in the bone marrow.
    Wang LC; Swat W; Fujiwara Y; Davidson L; Visvader J; Kuo F; Alt FW; Gilliland DG; Golub TR; Orkin SH
    Genes Dev; 1998 Aug; 12(15):2392-402. PubMed ID: 9694803
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta.
    Apperley JF; Gardembas M; Melo JV; Russell-Jones R; Bain BJ; Baxter EJ; Chase A; Chessells JM; Colombat M; Dearden CE; Dimitrijevic S; Mahon FX; Marin D; Nikolova Z; Olavarria E; Silberman S; Schultheis B; Cross NC; Goldman JM
    N Engl J Med; 2002 Aug; 347(7):481-7. PubMed ID: 12181402
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Leukemogenic Ptpn11 causes fatal myeloproliferative disorder via cell-autonomous effects on multiple stages of hematopoiesis.
    Chan G; Kalaitzidis D; Usenko T; Kutok JL; Yang W; Mohi MG; Neel BG
    Blood; 2009 Apr; 113(18):4414-24. PubMed ID: 19179468
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stem cell expression of the AML1/ETO fusion protein induces a myeloproliferative disorder in mice.
    Fenske TS; Pengue G; Mathews V; Hanson PT; Hamm SE; Riaz N; Graubert TA
    Proc Natl Acad Sci U S A; 2004 Oct; 101(42):15184-9. PubMed ID: 15477599
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multiple oligomerization domains of KANK1-PDGFRβ are required for JAK2-independent hematopoietic cell proliferation and signaling via STAT5 and ERK.
    Medves S; Noël LA; Montano-Almendras CP; Albu RI; Schoemans H; Constantinescu SN; Demoulin JB
    Haematologica; 2011 Oct; 96(10):1406-14. PubMed ID: 21685469
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Tel-Abl (ETV6-Abl) tyrosine kinase, product of complex (9;12) translocations in human leukemia, induces distinct myeloproliferative disease in mice.
    Million RP; Aster J; Gilliland DG; Van Etten RA
    Blood; 2002 Jun; 99(12):4568-77. PubMed ID: 12036890
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.